000 01588 a2200433 4500
005 20250515162520.0
264 0 _c20090429
008 200904s 0 0 eng d
022 _a1460-2105
024 7 _a10.1093/jnci/djp051
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHolzman, David
245 0 0 _aHas success spoiled hairy cell leukemia research? Key questions go unanswered, despite big gains.
_h[electronic resource]
260 _bJournal of the National Cancer Institute
_cMar 2009
300 _a370-3 p.
_bdigital
500 _aPublication Type: Historical Article; News
650 0 4 _aAnimals
650 0 4 _aAntibodies, Monoclonal
_xpharmacology
650 0 4 _aAntibodies, Monoclonal, Murine-Derived
650 0 4 _aAntineoplastic Agents
_xadverse effects
650 0 4 _aBiomedical Research
_xhistory
650 0 4 _aBone Marrow
_xdrug effects
650 0 4 _aCell Proliferation
_xdrug effects
650 0 4 _aCladribine
_xpharmacology
650 0 4 _aHistory, 20th Century
650 0 4 _aHistory, 21st Century
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xpharmacology
650 0 4 _aInterferons
_xpharmacology
650 0 4 _aLeukemia, Hairy Cell
_xdrug therapy
650 0 4 _aLeukocyte Count
650 0 4 _aLeukocytes
_xdrug effects
650 0 4 _aNucleosides
_xadverse effects
650 0 4 _aPentostatin
_xpharmacology
650 0 4 _aRituximab
650 0 4 _aWorkforce
773 0 _tJournal of the National Cancer Institute
_gvol. 101
_gno. 6
_gp. 370-3
856 4 0 _uhttps://doi.org/10.1093/jnci/djp051
_zAvailable from publisher's website
999 _c18716188
_d18716188